Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Randomized, Double-Blinded, Placebo-Controlled Dose Ranging Study to Evaluate Safety, Tolerability and Pharmacodynamics of a Single Intra-articular Injection of GNSC-001 Gene Therapy in Subjects With Osteoarthritis of the Knee

NCT05835895 is registered in ClinicalTrials.gov with Genascence Corporation as lead sponsor.

NCT NCT05835895
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05835895 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Randomized, Double-Blinded, Placebo-Controlled Dose Ranging Study to Evaluate Safety, Tolerability and Pharmacodynamics of a Single Intra-articular Injection of GNSC-001 Gene Therapy in Subjects With Osteoarthritis of the Knee
Lead sponsor
Genascence Corporation
Phase
Phase 1
Overall status
Active, not recruiting
Start date
June 12, 2023
Completion date
May 31, 2029
Enrollment
67 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

knee osteoarthritis, osteo arthritis knee, osteoarthritis, knee